Table 2.
Description Of The First Period Of AP Use During 2015
| All Antipsychotic Users | ||
|---|---|---|
| First Period Of Use | ||
| (N=1727) | ||
| Median (IQR) | ||
| Coverage in days | 73 (18–231) | |
| N | % | |
| Antipsychotic classification | ||
| Typical | 256 | 14.8 |
| Phenothiazines | 44 | 17.2 |
| Butyrophenone derivatives | 178 | 69.5 |
| Thioxanthene derivatives | 1 | 0.4 |
| Diphenylbutylpiperidine derivatives | 1 | 0.4 |
| Clotiapine | 19 | 7.4 |
| Benzamides excl amisulpride | 12 | 4.7 |
| Atypical | 1471 | 85.2 |
| Olanzapine, quetiapine | 1420 | 82.2 |
| Amisulpride | 4 | 0.2 |
| Other antipsychotics | 47 | 2.3 |
| Switch to another AP class within period of use | ||
| No | 1593 | 92.2 |
| Yes, starting with: | 134 | 7.8 |
| Typical | 64 | 47.8 |
| Atypical | 70 | 52.2 |
| Period of use | ||
| Up to 3 months | 958 | 55.5 |
| 1 month | 526 | 54.9 |
| 2 months | 262 | 27.3 |
| 3 months | 170 | 17.7 |
| More than 3 months | 769 | 44.6 |
| 4–6 months | 237 | 30.8 |
| 7–24 months | 242 | 31.5 |
| > 24 months | 300 | 39.0 |
| End of period due to: | ||
| Discontinuation | 1479 | 85.6 |
| Death | 3 | 0.1 |
| Study end | 245 | 11.9 |
Abbreviations: AP, antipsychotic; IQR, interquartile range.